Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance

Breast Cancer Research

Volumn 7, Issue 5, 2005, Pages

  Surowiak, Pawel ^a,b,c   Materna, Verena ^a   Matkowski, Rafal ^b   Szczuraszek, Katarzyna ^b   Kornafel, Jan ^b   Wojnar, Andrzej ^c   Pudelko, Marek ^c   Dietel, Manfred ^a   Denkert, Carsten ^a   Zabel, Maciej ^b   Lage, Hermann ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Wroclaw   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; LETROZOLE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROGESTERONE; TAMOXIFEN; GLYCOPROTEIN P;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; UPREGULATION; BREAST TUMOR; DISEASE COURSE; ENZYMOLOGY; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL; TIME;

BREAST NEOPLASMS; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; P-GLYCOPROTEIN; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 33344472746     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1313     Document Type: Article

References (31)

1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics. CA Cancer J Clin. 2002, 52: 23-47.
2. Mori I, Yang Q, Kakudo K: Predictive and prognostic markers for invasive breast cancer. Pathol Int. 2002, 52: 186-194 10.1046/j.1440-1827.2002.01335.x.
3. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ, Dreshler A, Fulton S, Hendricks CB, Kemeny M, Kornblith AB, Louis TA, Markman M, Mayer R, Roter D: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001, 90 (13): 979-989.
4. Goldhirsch A, Glick JH, Gelber RD: Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst. 1998, 90: 1601-1608 10.1093/jnci/90.21.1601.
5. Lage H: ABC-transporters: implications on drug resistance from microorganisms to human cancer. Int J Antimicrob Agents. 2003, 22: 188-199 10.1016/S0924-8579(03)00203-6.
6. Lage H: Drug resistance in breast cancer. Cancer Therapy. 2003, 1: 81-91.
7. Gasparini G, Longo R, Sarmiento R, Morabito A: Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. Lancet Oncol. 2003, 4: 605-615 10.1016/S1470-2045(03)01220-8.
8. Ristimäki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, Haglund C: Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol. 2001, 158: 849-853.
9. Denkert C, Kobel M, Pest S, Koch I, Licht D, Kobel M, Reles A, Sehouli J, Dietel M, Hauptmann S: Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol. 2002, 160: 893-903.
10. Denkert C, Kobel M, Berger S, Kobel M, Siegert A, Hauptmann S: Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 2001, 61: 303-308.
11. Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, Kristiansen G, Reles A, Siegert A, Guski H, Hauptmann S: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003, 97: 2978-2987 10.1002/cncr.11437.
12. Brueggemeier RW, Richards JA, Petrel TA: Aromatase and cyclooxygenase in breast cancer. J Steroid Biochem Mol Biol. 2003, 86: 501-507 10.1016/S0960-0760(03)00380-7.
13. Davies G, Martin LA, Sacks N, Dowsett M: Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol. 2002, 13: 669-678 10.1093/annonc/mdf125.
14. Patel VA, Dunn MJ, Sorokin A: Regulation of MDR1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem. 2002, 277: 38915-38920 10.1074/jbc.M206855200.
15. Sobin LH, Wittekind C: TNM classification of malignant tumours. 2002, New York: Wiley-Liss Inc, 5
16. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410.
17. Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987, 8: 138-140.
18. Denkert C, Weichert W, Pest S, Koch I, Licht D, Kobel M, Reles A, Sehouli J, Dietel M, Hauptmann S: Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res. 2004, 64: 189-195.
19. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connoly JL, et al: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000, 124: 966-978.
20. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, et al: Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumours: consensus recommendations. Cancer Res. 1996, 56: 3010-3020.
21. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002, 62: 632-635.
22. Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M, Takebayashi Y: Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res. 2001, 92: 452-458.
23. Hennequin E, Delvincourt C, Pournz C, Jardillier JC: Expression of mdr1 gene in human breast primary tumours and metastases. Breast Cancer Res Treat. 1993, 26: 267-274 10.1007/BF00665804.
24. Decker DA, Morris LW, Levine AJ, Pettinga JE, Grudzien JL, Farkas DH: Immunohistochemical analysis of P-glycoprotein expression in breast cancer: clinical correlations. Ann Clin Lab Sci. 1995, 25: 52-59.
25. Sun SS, Hsieh JF, Tsai SC, Ho YJ, Lee JK, Kao CH: Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results. Cancer Lett. 2000, 153: 95-100 10.1016/S0304-3835(00)00356-6.
26. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002, 2: 48-58 10.1038/nrc706.
27. Materna V, Pleger J, Hoffmann U, Lage H: RNA expression of MDR1/P-glyocprotein, DNA-topoisomerase, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol. 2004, 94: 152-160 10.1016/j.ygyno.2004.03.035.
28. Linn SC, Giaccone G, van Diest PJ, Blokhuis WM, van der Valk P, van Kalken CK, Kuiper CM, Pinedo HM, Baak JP: Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol. 1995, 6: 679-685.
29. Nooter K, Brutel DLR, Look MP, van Wingerden KE, Henzen-Logmans SC, Scheper RJ, Flens MJ, Klijn JG, Stoter G, Foekens JA: The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer. 1997, 76: 486-493.
30. L: a molecular pathway of H pylori-related gastric carcinogenesis. J Pathol. 2004, 202: 305-312 10.1002/path.1512.
31. Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC, Tangera JA: Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?. Anticancer Res. 2001, 21: 2141-2147.